Literature DB >> 36168727

Corrigendum.

.   

Abstract

Entities:  

Year:  2022        PMID: 36168727      PMCID: PMC9515701          DOI: 10.1002/npr2.12270

Source DB:  PubMed          Journal:  Neuropsychopharmacol Rep        ISSN: 2574-173X


× No keyword cloud information.
In Kishi et al., Table 2 and Appendix S2 were published with incorrect data for blood triglyceride, blood total cholesterol, and fasting blood glucose.
TABLE 2
Blood triglyceride
LUR400.038 (−0.153, 0.230)0.028 (−0.148, 0.205)−0.424, 0.480
0.078 (−0.121, 0.278)LUR80−0.010 (−0.216, 0.197)−0.494, 0.475
0.049 (−0.131, 0.229)0.011 (−0.218, 0.239)PlaceboPrediction interval*
This study represents collaborating research between Fujita Health University School of Medicine and Sumitomo Dainippon Pharma Co., Ltd (Sumitomo). After the publication, Sumitomo realized that they had provided the incorrect clinical trial (P3‐J066) dataset regarding blood triglyceride, blood total cholesterol, and fasting blood glucose to Fujita Health University School of Medicine. The data must include only fasting measurement data, but the original data included some non‐fasting measurement data. Therefore, Sumitomo asked Dr. Kishi of Fujita Health University School of Medicine to reanalyze these parameters. The correct Table 2 is presented below, while Appendix S2 has been corrected in the online version. Sumitomo accepts full responsibility and apologizes for these errors. Figure S1 Click here for additional data file.
  1 in total

1.  Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.

Authors:  Taro Kishi; Tadashi Nosaka; Kenji Sakuma; Makoto Okuya; Nakao Iwata
Journal:  Neuropsychopharmacol Rep       Date:  2020-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.